Barrington analyst Michael Petusky maintained a Buy rating on Opko Health (OPK) today and set a price target of $4. The company’s shares closed last Monday at $2.15, close to its 52-week low of $1.73.
Petusky wrote:
“We continue to rate OPK shares an OUTPERFORM and our price target remains $4. That said, if the company were to receive a strong data readout from its Phase III trial for hGH‐CTP within the next few months, we suspect that shares would rally meaningfully from current levels and that investor sentiment could swing positive for the first time in over four years. We arrive at our price target via a DCF methodology. It is important to note that the company still has many “shots on goal” within its current commercial portfolio and product development pipeline.”
According to TipRanks.com, Petusky is a 4-star analyst with an average return of 4.4% and a 52.8% success rate. Petusky covers the Healthcare sector, focusing on stocks such as Anika Therapeutics Inc, Varian Medical Systems, and Merit Medical Systems.
Currently, the analyst consensus on Opko Health is a Moderate Buy with an average price target of $4.
See today’s analyst top recommended stocks >>
The company has a one-year high of $5.72 and a one-year low of $1.73. Currently, Opko Health has an average volume of 3.67M.
Based on the recent corporate insider activity of 70 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of OPK in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
OPKO Health, Inc. engages in the provision of healthcare services. It operates through the Diagnostics and Pharmaceuticals segments. The Diagnostics segment comprises clinical laboratory operations which acquired through the Bio-Reference and point-of-care operations.
